- Incyte to Report First Quarter Financial Results
- Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
- Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
- Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
- New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
- Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
- Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
- Incyte to Present at Upcoming Investor Conference
- Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
More ▼
Key statistics
As of last trade Incyte Corp (INCY:NSQ) traded at 52.13, 3.70% above its 52-week low of 50.27, set on Oct 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 52.97 |
---|---|
High | 53.00 |
Low | 52.04 |
Bid | 52.11 |
Offer | 52.15 |
Previous close | 52.82 |
Average volume | 1.55m |
---|---|
Shares outstanding | 224.53m |
Free float | 220.96m |
P/E (TTM) | 19.98 |
Market cap | 11.86bn USD |
EPS (TTM) | 2.64 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 20:03 BST.
More ▼